Colorectal Gastrointestinal Stromal Tumors: A Brief Review

Rishindra M. Reddy; James W. Fleshman

doi:10.1055/s-2006-942347

Clinics in Colon and Rectal Surgery, Inhaltsverzeichnis

Clin Colon Rectal Surg 2006; 19(2): 069-077
DOI: 10.1055/s-2006-942347

Colorectal Gastrointestinal Stromal Tumors: A Brief Review

Rishindra M. Reddy¹ , James W. Fleshman²

¹Department of Surgery, Washington University School of Medicine, St. Louis, Missouri
²Section of Colon and Rectal Surgery; Washington University School of Medicine, St. Louis, Missouri

Abstract

ABSTRACT

Gastrointestinal stromal tumors (GISTs) are rare lesions that constitute the majority of mesenchymal tumors in the gastrointestinal tract. Within the colon and rectum, they represent 0.1% of all cancers. They can present with a variety of symptoms but are often asymptomatic. Although many lesions may be benign, up to half of patients develop recurrent disease within a few years. Almost all GISTs contain a mutation in the c-kit tyrosine kinase that leads to its constitutive activation and results in cell proliferation. This discovery has led to the immunostaining of the c-kit antigen (CD117) to distinguish GISTs from other malignancies. Radiologic examinations can be helpful in initial diagnosis and staging. Surgery is the best treatment for cure, but recent advances have led to the use of imatinib mesylate, a tyrosine kinase inhibitor, to treat metastatic or unresectable disease, or both. There are currently many clinical trials available to help treat GISTs.

KEYWORDS

Gastrointestinal stromal tumors - colon cancer - imatinib mesylate - CD117/c-kit - surgery

Volltext

Referenzen

REFERENCES

1 Pidhorecky I, Cheney R T, Kraybill W F, Gibbs J F. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol. 2000; 7 705-712
2 Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer. 2002; 38(suppl 5) S39-S51
3 Stout A P. Bizarre smooth muscle tumors of the stomach. Cancer. 1962; 15 400-409
4 Appelman H D. Smooth muscle tumors of the gastrointestinal tract. What we know now that Stout didn't know. Am J Surg Pathol. 1986; 10(suppl 1) 83-99
5 Mazur M T, Clark H B. Gastric stromal tumors: reappraisal of histogenesis. Am J Surg Pathol. 1983; 7 507-519
6 Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol. 1999; 30 1213-1220
7 Nilsson B, Bumming P, Meis-Kindblom J M et al.. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era. Cancer. 2005; 103 821-829
8 Robinson T L, Sircar K, Hewlett B R, Chorneyko K, Riddel R H, Huizinga J D. Gastrointestinal stromal tumors may originate from a subset of CD34-positive interstitial cells of Cajal. Am J Pathol. 2000; 156 1157-1163
9 Sircar K, Hewlett B R, Huizinga J D, Chorneyko K, Berezin I, Riddell R H. Interstitial cells of Cajal as precursors for gastrointestinal stromal tumors. Am J Surg Pathol. 1999; 23 377-389
10 Kindblom L G, Remotti H E, Aldenborg F, Meis-Kindblom J M. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998; 152 1259-1269
11 Berman J, O'Leary T J. Gastrointestinal Stromal Tumor Workshop. Hum Pathol. 2001; 32 578-582
12 Miettinen M, Furlong M, Sarlomo-Rikala M, Burke A, Sobin L H, Lasota J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol. 2001; 25 1121-1133
13 Hirota S, Isozaki K, Moriyama Y et al.. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998; 279 577-580
14 http://www.glivec.com/images/
15 Tuveson D A, Willis N A, Jacks T et al.. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001; 20 5054-5058
16 Hirota S, Nishida T, Isozaki K et al.. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol. 2001; 193 505-510
17 van der Zwan S M, DeMatteo R P. Gastrointestinal stromal tumor: 5 years later. Cancer. 2005; 104 1781-1788
18 Tran T, Davila J A, El-Serag H B. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol. 2005; 100 162-168
19 Hasegawa T, Matsuno Y, Shimoda T, Hirohashi S. Gastrointestinal stromal tumors: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol. 2002; 33 669-676
20 Miettinen M, Sarlomo-Rikala M, Sobin L H, Lasota J. Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases. Am J Surg Pathol. 2000; 24 1339-1352
21 Conlon K C, Casper E S, Brennan M F. Primary gastrointestinal sarcomas: analysis of prognostic variables. Ann Surg Oncol. 1995; 2 26-31
22 DeMatteo R P, Lewis J J, Leung D, Mudan S S, Woodruff J M, Brennan M F. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000; 231 51-58
23 Burkill G JC, Badran M, Al-Muderis O et al.. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology. 2003; 226 527-532
24 Orosz Z, Tornoczky T, Sapi Z. Gastrointestinal stromal tumors: a clinicopathologic and immunohistochemical study of 136 cases. Pathol Oncol Res. 2005; 11 11-21
25 Greenson J K. Gastrointestinal stromal tumors and other mesenchymal lesions of the gut. Mod Pathol. 2003; 16 366-375
26 Horton K M, Juluru K, Montogomery E, Fishman E K. Computed tomography imaging of gastrointestinal stromal tumors with pathology correlation. J Comput Assist Tomogr. 2004; 28 811-817
27 Emory T S, Sobin L H, Lukes L, Lee D H, O'Leary T J. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol. 1999; 23 82-87
28 Tateishi U, Hasegawa T, Satake M, Moriyama N. Gastrointestinal stromal tumor; correlation of computed tomography findings with tumor grade and mortality. J Comput Assist Tomogr. 2003; 27 792-798
29 Kurokawa Y, Nishisho I, Kawahara K, Mishima H, Hirota S, Kikkawa N. Gastrointestinal stromal tumor of the rectum with activating mutation of c-kit: report of a case. Dis Colon Rectum. 2000; 43 1316-1318
30 Shibata Y, Ueda T, Seki H, Yagihashi N. Gastrointestinal stromal tumour of the rectum. Eur J Gastroenterol Hepatol. 2001; 13 283-286
31 Michalopoulos A, Papadopoulos V N, Basdanis G et al.. Colorectal gastrointestinal mesenchymal tumours. Report of a stromal case of the rectum (GIST) and leiomyosarcoma of the transverse colon. Tech Coloproctol. 2004; 8(suppl 1) s155-s157
32 Lo S S, Papachristou G I, Finkelstein S D, Conroy W P, Schraut W H, Ramanathan R K. Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: report of a case. Dis Colon Rectum. 2005; 48 1316-1319
33 Gupta S, Punia R S, Kaushik R. Gastrointestinal stromal tumour of the colon presenting with intestinal obstruction. Indian J Cancer. 2004; 41 175-177
34 Neuhaus S J, Clark M A, Hayes A J, Thomas J M, Judson I. Surgery for gastrointestinal tumour in the post-imatinib era. ANZ J Surg. 2005; 75 165-172
35 Levy A D, Remotti H E, Thompson W M, Sobin L H, Miettinen M. Anorectal gastrointestinal stromal tumors: CT and MR imaging features with clinical and pathologic correlation. AJR Am J Roentgenol. 2003; 180 1607-1612
36 Tworek J A, Goldblum J R, Weiss S W, Greenson J K, Appelman H D. Stromal tumors of the anorectum: a clinicopathologic study of 22 cases. Am J Surg Pathol. 1999; 23 946-954
37 McGrath P C, Neifeld J P, Lawrence Jr W, Kay S, Horsley III J S, Parker G A. Gastrointestinal sarcomas. Analysis of prognostic factors. Ann Surg. 1987; 206 706-710
38 Hama Y, Okizuka H, Odajima K, Hayakawa M, Kusano S. Gastrointestinal stromal tumor of the rectum. Eur Radiol. 2001; 11 216-219
39 Van den Berg J C, van Heesewijk J P, van Es H W. Malignant stromal tumour of the rectum: findings at endorectal ultrasound and MRI. Br J Radiol. 2000; 73 1010-1012
40 Hsieh J S, Huang C J, Wang J Y, Huang T J. Benefits of endorectal ultrasound for management of smooth-muscle tumor of the rectum: report of three cases. Dis Colon Rectum. 1999; 42 1085-1088
41 Connolly E M, Gaffney E, Reynolds J V. Gastrointestinal stromal tumours. Br J Surg. 2003; 90 1178-1186
42 Fletcher C D, Berman J J, Corless C et al.. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002; 33 459-465
43 Tworek J, Goldblum J R, Weiss S W, Greenson J K, Appelman H D. Stromal tumors of the abdominal colon: a clinicopathologic study of 20 cases. Am J Surg Pathol. 1999; 23 937-945
44 Miettinen M, Sobin L H, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol. 2000; 13 1134-1142
45 Miettinen M, Lasota J. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol. 2003; 54 3-24
46 Sarlomo-Rikala M, Kovatich A J, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol. 1998; 11 728-734
47 Yamaguchi U, Hasegawa T, Masuda T et al.. Differential diagnosis of gastrointestinal stromal tumor and other spindle cell tumors in the gastrointestinal tract based on immunohistochemical analysis. Virchows Arch. 2004; 445 142-150
48 Daum O, Hes O, Vanecek T et al.. Vanek's tumor(inflammatory fibroid polyp). Report of 18 cases and comparison with three cases of original Vanek's series. Ann Diagn Pathol. 2003; 7 337-347
49 Miettinen M, Sarlomo-Rikala M, Sobin L H. Mesenchymal tumors of muscularis mucosae of colon and rectum are benign leiomyomas that should be separated from gastrointestinal stromal tumors-a clinicopathologic and immunohistochemical study of eighty-eight cases. Mod Pathol. 2001; 14 950-956
50 Dougherty M J, Compton C, Talbert M, Wood W C. Sarcomas of the gastrointestinal tract. Separation into favorable and unfavorable prognostic groups by mitotic count. Ann Surg. 1991; 214 569-574
51 Lee C H, Jan Y J, Chen J T, Ho W L, Tseng C H, Wang J. Colorectal mesenchymal tumor: a clinicopathologic study of 25 cases. J Chin Med Assoc. 2005; 68 291-298
52 Haque S, Dean P J. Stromal neoplasms of the rectum and anal canal. Hum Pathol. 1992; 23 762-767
53 Chak A, Canto M I, Rosch T et al.. Endosonographic differentiation of benign and malignant stromal cell tumors. Gastrointest Endosc. 1997; 45 468-473
54 Taniguchi M, Nishida T, Hirota S et al.. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res. 1999; 59 4297-4300
55 Sturgeon C, Chejfec G, Espat N J. Gastrointestinal stromal tumors: a spectrum of disease. Surg Oncol. 2003; 12 21-26
56 Plaat B E, Hollema H, Molenaar W M et al.. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol. 2000; 18 3211-3220
57 Masuoka H, Kawagishi N, Inoue T et al.. Giant hepatic metastasis from gastrointestinal stromal tumor of the rectum 12 years after surgery. Hepatogastroenterology. 2003; 50 1454-1456
58 Lanteri R, Aliotta I, Racalbuto A, Licata A. Anal GIST in older old patient: a case report. G Chir. 2005; 26 135-137
59 Van Oosterom A T, Judson I, Verweij J et al.. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study. Lancet. 2001; 358 1421-1423
60 Demetri G D, von Mehren M, Blanke C D et al.. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347 472-480
61 Van Glabbeke M, Verweij J, Casali P G et al.. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol. 2005; 23 5795-5804
62 Dagher R, Cohen M, Williams G et al.. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res. 2002; 8 3034-3038
63 Vanel D, Albiter M, Shapeero L et al.. Role of computed tomography in the follow-up of hepatic and peritoneal metastases of GIST under imatinib mesylate treatment: a prospective study of 54 patients. Eur J Radiol. 2005; 54 118-123
64 Joensuu H, Roberts P J, Sarlomo-Rikala M et al.. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001; 344 1052-1056
65 Antoch G, Kanja J, Bauer S et al.. Comparison of PE, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med. 2004; 45 357-365
66 Scaife C L, Hunt K K, Patel S R et al.. Is there a role for surgery in patients with “unresectable” cKIT + gastrointestinal stromal tumors treated with imatinib mesylate?. Am J Surg. 2003; 186 665-669
67 Koon N, Schneider-Stock R, Sarlomo-Rikala M et al.. Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut. 2004; 53 235-240
68 http://www.cancer.gov/clinicaltrials/

Rishindra M ReddyM.D.

Department of Surgery, Washington University School of Medicine, House Staff Office

Campus Box 8109, 1701 West Bldg., 660 S. Euclid Ave., St. Louis, MO 63110

eMail: reddyr@wudosis.wustl.edu